• Profile

Echocardiography for the diagnosis of CTRCD in women with early-stage breast cancer

JAMA Feb 12, 2022

In clinical practice, timely diagnosis of cancer therapy–related cardiac dysfunction (CTRCD) could be improved via combined use of echocardiography 3-dimensional (3-D) left ventricular ejection fraction (LVEF), global longitudinal strain (GLS), and global circumferential strain (GCS).

  • Researchers assessed the correctness of an algorithm employing echocardiography and serum biomarkers for the timely diagnosis of CTRCD defined using cardiovascular magnetic resonance (CMR).

  • In this cohort study, a total of 136 women (mean [SD] age, 51.1 [9.2] years) with human epidermal growth factor receptor 2–positive early-stage breast cancer were included.

  • Exposures included sequential therapy with anthracyclines and trastuzumab.

  • Good discriminatory accuracy for concurrent CMR-detected CTRCD was achieved with a combined approach of using echocardiographic 3-D LVEF, GLS, and GCS, but not by high-sensitivity troponin I and B-type natriuretic.

  • The likelihood of CTRCD as defined by CMR was 1.0% when none of the 3-D LVEF, GLS, and GCS CTRCD criteria were met.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen